Who
Roberto Mignone
Director
Company insider
Files Form 4 as: Director, Guardant Health; Director, Teva Pharmaceutical Industries; Director, Avanti Acquisition; 10% owner, Response Genetics; Other, Cardiff Oncology; 10% owner, Orchid Cellmark; 10% owner, Trimeris.
In numbers
- Trades disclosed
- 99
- Buys
- 8
- Sells
- 6
- Bought
- $26.5M
- Sold
- $52.3M
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 21 Aug 2007
- Last trade
- 21 Sep 2026
- Last filed
- 22 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Sep 2026filed 22 Sep 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —264 at $0.00 | filing |
| 21 Sep 2026filed 22 Sep 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —264 at $0.00 | filing |
| 21 Sep 2026filed 22 Sep 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —264 at $0.00 | filing |
| 21 Sep 2026filed 22 Sep 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —264 at $0.00 | filing |
| 18 Sep 2026filed 22 Sep 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $14.4M367,600 at $39.06 | filing |
| 18 Sep 2026filed 22 Sep 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $14.4M367,600 at $39.06 | filing |
| 21 Aug 2026filed 24 Aug 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —264 at $0.00 | filing |
| 21 Aug 2026filed 24 Aug 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —264 at $0.00 | filing |
| 21 Aug 2026filed 24 Aug 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —264 at $0.00 | filing |
| 21 Aug 2026filed 24 Aug 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —264 at $0.00 | filing |
| 21 Jul 2026filed 22 Jul 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —264 at $0.00 | filing |
| 21 Jul 2026filed 22 Jul 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —264 at $0.00 | filing |
| 21 Jul 2026filed 22 Jul 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —264 at $0.00 | filing |
| 21 Jul 2026filed 22 Jul 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —264 at $0.00 | filing |
| 21 Jun 2026filed 23 Jun 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —264 at $0.00 | filing |
| 21 Jun 2026filed 23 Jun 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —264 at $0.00 | filing |
| 21 Jun 2026filed 23 Jun 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —264 at $0.00 | filing |
| 21 Jun 2026filed 23 Jun 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —264 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —4,203 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —4,203 at $0.00 | filing |
News
Comparing Harrow (NASDAQ:HROW) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 16 Oct 2026Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $50.00TEVA · dailypolitical.com · 15 Oct 2026Analyzing Astrazeneca (NYSE:AZN) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name Roberto Mignone; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.